Company Filing History:
Years Active: 2023-2024
Title: Innovator Spotlight: Jun-Su Ban
Introduction: Jun-Su Ban is a prominent inventor based in Hwaseong-si, South Korea, known for his significant contributions to pharmaceuticals. With a total of two patents to his name, Ban focuses on developing innovative compounds aimed at treating various medical conditions through targeted inhibition.
Latest Patents: Jun-Su Ban's latest patents highlight his expertise in developing cutting-edge pharmaceutical solutions. One of his notable inventions involves autotaxin (ATX) inhibitor compounds. This patent details methods for using these compounds and compositions to inhibit ATX, along with strategies for their preparation and synthetic precursors.
The second patent showcases Ban's contribution as he presents substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1-f][1,2,4]triazines acting as dual inhibitors for androgen receptor (AR) and phosphodiesterase 5 (PDE-5). This innovation provides solutions for inhibiting both AR and PDE-5, offering dual functionality for potential therapies.
Career Highlights: Jun-Su Ban is associated with Il Dong Pharmaceutical Co., Ltd., where he continues to push the boundaries of pharmaceutical research and development. His role in the company underscores his commitment to advancing medical science and enhancing treatment options for various conditions.
Collaborations: Throughout his career, Ban has worked alongside talented professionals, including his coworkers Jeong-Ah Kim and Soo-Jin Lee. These collaborations reflect a strong team dynamic focused on fostering innovations that could lead to significant breakthroughs in healthcare.
Conclusion: With a solid track record of patenting innovative compounds, Jun-Su Ban exemplifies the spirit of innovation in the pharmaceutical industry. His work not only advances scientific knowledge but also holds the promise of improved medical therapies for patients worldwide. The ongoing research and developments by Ban and his team at Il Dong Pharmaceutical Co., Ltd. continue to impact the landscape of pharmaceutical innovation significantly.